ChemoCentryx Shares Rise 10% After Filing NDA Amendment for Avacopan

   By Chris Wack 
 

ChemoCentryx Inc. shares were up 10% at $14.52 after the company said that, following consultations with the U.S. Food and Drug Administration, it filed an amendment to its New Drug Application for avacopan for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

The company said the amendment addresses points raised during an FDA Advisory Committee meeting on May 6.

The FDA has indicated that the filing constitutes a major amendment to the NDA and will result in the setting of a new Prescription Drug User Fee Act goal date of Oct. 7. The NDA is primarily based on data from a Phase III trial of avacopan for the treatment of ANCA-associated vasculitis.

On May 6, the FDA's Arthritis Advisory Committee voted 9-9 on whether the efficacy data support approval of avacopan, 10-8 that the safety profile of avacopan is adequate to support approval, and 10-8 that the benefit-risk profile is adequate to support approval of avacopan at the proposed dose of 30 mg twice daily.

The Marketing Authorization Application for avacopan in the treatment of ANCA-associated vasculitis was validated by the European Medicines Agency in November 2020, and the Japanese New Drug Application was accepted for review by the Japanese Pharmaceuticals and Medical Device Agency in February.

Volume for the stock was 9 million shares at 12:45 p.m. ET, compared with its 65-day average volume of 3.6 million shares. The stock hit its 52-week low of $9.53 on May 25.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

July 06, 2021 13:05 ET (17:05 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.